about
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeSequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesMetastatic melanoma: chemotherapy.Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.Treatment of cancer-related anemia with epoetin alfa: a review.Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon.A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.Impressive objective response in a patient with extensive metastatic melanoma including the brain.Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.[AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumab].T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanomaImmunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I TrialDoxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimensA randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neckUnusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanomaAllovectin-7 therapy in metastatic melanomaNeuroendocrine tumors (NETs)Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit RatioInvestigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
P50
Q27853295-ABC1CBE4-6868-4CCF-818E-18F570B2944CQ30746423-380AF9C5-1C25-4BC7-9DD3-F608918EC564Q30828178-70DB917D-2C4F-40CF-BD88-6A72DB619881Q33433902-D3058049-B5A4-4A14-8C65-79A528FA1D7AQ33620317-96120F2E-79DB-49AD-A617-12BCAF9D45DBQ34156931-410C38BE-8D48-40A3-84CB-7AF0439C8357Q34656538-DB88C890-3B1F-4908-894C-173324376434Q35868988-C26B5BE3-68F7-472E-8175-6F42E663C4BBQ36089197-034F717A-9B8B-4C51-B197-8AA39871ACFDQ37681718-56E0892C-E41C-4EF0-944C-15441A8EC06EQ38195330-9B790B8B-05DC-4591-83AA-558BD87C1959Q38593792-96E43552-493B-49A2-A45A-187551E6E82CQ38938622-5F8A6B3E-EA0C-4B67-AB7D-2F25C6F33FD0Q39009684-DEAF33D0-F1F6-4393-97B8-37F7A935C34EQ40070782-8D6EDBF3-C3ED-4A7C-A893-A5C324AAFD1BQ41972051-B52B8727-44B9-471B-BB25-29DD15A5264FQ42645881-95417A53-7392-4758-B2F0-335C96AA8EA0Q42844316-EBAF8F5E-E720-44FC-B0E7-C538084E5D5EQ43127268-D6CE99C5-C8ED-4C47-AAD9-787E33755646Q45197443-2D7D8C21-399F-497C-B626-69F3724EECC7Q46937324-A5923A0E-92CB-47D9-88D1-2A1972D74165Q46988917-5D284EB0-8F1D-4928-B1F3-C5551AF43A40Q48401064-7F62D375-8894-43C3-A997-7916F78C3C2CQ50147228-623DD77C-BC57-4468-A60A-8B205D407A06Q51833630-C8D4CCF6-B645-439C-8390-541073CB9537Q56898443-58F85BA6-A655-4BF0-8070-79C32C76C958Q57081488-925BDB94-6B82-4E91-964A-3E965C121040Q61628367-FAEAAEC1-5DF2-44D2-A1C8-D193932121B1Q72695844-9CA53E78-A452-4ED6-B5F4-D65D3FBD72EBQ76332830-9F277918-35DB-4D73-8537-1DE59DC67463Q81267809-CC4E035E-E39A-4AD6-A97E-D4F6B7FADB1EQ84753923-CE08289B-D9B1-48C4-9854-6D47D381C9E5Q87115825-DAE1B1B8-4C7A-4F97-A6A9-130DDF72EB24Q90431041-A275CFF4-5C95-4723-844F-B9635F1B7A4D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michele Del Vecchio
@ast
Michele Del Vecchio
@en
Michele Del Vecchio
@es
Michele Del Vecchio
@nl
Michele Del Vecchio
@sl
type
label
Michele Del Vecchio
@ast
Michele Del Vecchio
@en
Michele Del Vecchio
@es
Michele Del Vecchio
@nl
Michele Del Vecchio
@sl
prefLabel
Michele Del Vecchio
@ast
Michele Del Vecchio
@en
Michele Del Vecchio
@es
Michele Del Vecchio
@nl
Michele Del Vecchio
@sl
P1053
K-1584-2016
P106
P1153
18534781300
P31
P3829
P496
0000-0001-9060-2512